CANF vs. BRTX, NAVB, PHXM, EIGR, GLTO, EFTR, HEPA, CMMB, CVKD, and TRVN
Should you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include BioRestorative Therapies (BRTX), Navidea Biopharmaceuticals (NAVB), PHAXIAM Therapeutics (PHXM), Eiger BioPharmaceuticals (EIGR), Galecto (GLTO), eFFECTOR Therapeutics (EFTR), Hepion Pharmaceuticals (HEPA), Chemomab Therapeutics (CMMB), Cadrenal Therapeutics (CVKD), and Trevena (TRVN). These companies are all part of the "medical" sector.
Can-Fite BioPharma (NYSE:CANF) and BioRestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 69.4% of BioRestorative Therapies shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 21.6% of BioRestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Can-Fite BioPharma has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 62.1, indicating that its share price is 6,110% more volatile than the S&P 500.
Can-Fite BioPharma has higher revenue and earnings than BioRestorative Therapies. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than BioRestorative Therapies, indicating that it is currently the more affordable of the two stocks.
Can-Fite BioPharma has a net margin of -1,027.46% compared to BioRestorative Therapies' net margin of -9,873.97%. Can-Fite BioPharma's return on equity of -113.75% beat BioRestorative Therapies' return on equity.
Can-Fite BioPharma received 1 more outperform votes than BioRestorative Therapies when rated by MarketBeat users.
In the previous week, BioRestorative Therapies had 7 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 8 mentions for BioRestorative Therapies and 1 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.00 beat BioRestorative Therapies' score of -0.06 indicating that Can-Fite BioPharma is being referred to more favorably in the media.
Can-Fite BioPharma currently has a consensus price target of $15.00, indicating a potential upside of 638.92%. Given Can-Fite BioPharma's higher probable upside, research analysts clearly believe Can-Fite BioPharma is more favorable than BioRestorative Therapies.
Summary
Can-Fite BioPharma beats BioRestorative Therapies on 10 of the 16 factors compared between the two stocks.
Get Can-Fite BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Can-Fite BioPharma Competitors List
Related Companies and Tools
